Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

18.3K
Here we describe cellular cytotoxicity and single round infectivity assays that allow for the rapid and accurate screening of compounds to determine their cellular cytotoxicity (CC50) and IC50 values against WT and drug resistant...
18.3K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

32.1K
Quantifying levels of HIV-1 RNA in plasma and sequencing single HIV-1 genomes from individuals with viral loads below the limit of detection (50-75 copies/ml) is difficult. Here we describe how to extract and quantify plasma viral RNA using a real time PCR assay that reliably measures HIV-1 RNA down to 0.3 copies/ml and how to amplify viral genomes by single genome sequencing, from samples with very low viral...
32.1K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

19.1K
Drug resistance testing for HIV-1 infected individuals failing antiretroviral therapy (ART) can guide future therapies and improve treatment outcomes. Optimizing individual and population health outcomes in high HIV prevalence but resource-limited settings will ultimately require affordable and accessible drug resistance genotyping and interpretation...
19.1K
Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

8.2K
Methods to evaluate the efficacy and toxicity of RNA molecules targeting post-integration steps of the HIV-1 replication cycle are described. These methods are useful for screening new molecules and optimizing the format of existing ones.
8.2K
Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V311:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

12.7K
HIV tropism can be inferred from the V3 region of the viral envelope. V3 is PCR amplified in triplicate using nested RT-PCR, sequenced, and interpreted using bioinformatic software. Samples with with 1 or more sequence(s) with low g2P scores are classified as non-R5...
12.7K
Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection08:15

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

9.1K
We have developed a protocol for the generation and evaluation of a humanized and human immunodeficiency virus-infected NOG mouse model based on stem cell transplant, intravaginal human immunodeficiency virus exposure, and droplet digital PCR RNA...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NfL makes regulatory debut as neurodegenerative disease biomarker.

Nature reviews. Drug discovery·2023
Same author

NCATS's plan to grow the rare disease pipeline.

Nature reviews. Drug discovery·2023
Same author

GSK buys purine receptor antagonist for $2 billion.

Nature reviews. Drug discovery·2023
Same author

FDA approves second microbiome-based C. difficile therapy.

Nature reviews. Drug discovery·2023
Same author

Astellas buys complement inhibitor for $5.9 billion.

Nature reviews. Drug discovery·2023
Same author

Setting GPCRs free.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Jan 20, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.3K

Longer-lasting HIV drugs

Asher Mullard

    Nature Reviews. Drug Discovery
    |September 4, 2019
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
    13:58

    Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

    Published on: September 26, 2011

    32.1K
    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    19.1K

    Related Experiment Videos

    Last Updated: Jan 20, 2026

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
    05:46

    Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

    Published on: April 9, 2014

    18.3K
    Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
    13:58

    Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

    Published on: September 26, 2011

    32.1K
    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
    19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    19.1K